|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of ABCB1 mRNA naringenin inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; naringenin inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]]; naringenin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] |
CTD |
PMID:19148864 PMID:34217736 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions increases activity |
ISO |
[Glutathione co-treated with naringenin] inhibits the reaction [ABCC1 protein results in increased uptake of estradiol-17 beta-glucuronide]; Glutathione promotes the reaction [naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [naringenin results in increased activity of ABCC1 protein]; naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; naringenin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; naringenin inhibits the reaction [ABCC1 protein results in increased export of S-(2,4-dinitrophenyl)glutathione]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased uptake of Glutathione] |
CTD |
PMID:11306701 PMID:12485947 PMID:16156793 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:16156793 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
naringenin inhibits the reaction [ABCC5 protein results in decreased susceptibility to Thioguanine]; naringenin inhibits the reaction [ABCC5 protein results in increased export of 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16156793 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
naringenin inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein] |
CTD |
PMID:14709902 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of ADGRB1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ADGRB1 mRNA naringenin metabolite results in increased expression of ADGRB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
naringenin binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity multiple interactions |
ISO |
naringenin results in increased activity of AHR protein naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AHR protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]] |
CTD |
PMID:17869316 PMID:20450880 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
naringenin binds to and results in decreased activity of AKR1C1 protein |
CTD |
PMID:16962702 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
naringenin results in decreased activity of AKR1C3 protein |
CTD |
PMID:19007764 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
ISO EXP |
naringenin inhibits the reaction [bisphenol A results in increased activity of AKT1 protein]; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of AKT1 protein] naringenin results in decreased expression of AKT1 mRNA naringenin inhibits the reaction [lead acetate results in decreased expression of AKT1 protein]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22692793 PMID:22709785 PMID:25866363 PMID:36807407 PMID:36819991 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in increased expression of ALB protein]; naringenin inhibits the reaction [tyloxapol results in decreased expression of ALB mRNA] |
CTD |
PMID:31063766 PMID:37076581 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[naringenin binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[naringenin binds to ESR1 protein] which results in increased activity of ALPL protein] |
CTD |
PMID:12650720 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of APAF1 mRNA; naringenin results in increased expression of APAF1 protein [naringenin co-treated with bisphenol A] results in increased expression of APAF1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of APAF1 mRNA |
CTD |
PMID:27838343 PMID:36235125 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
naringenin inhibits the reaction [APP protein modified form results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:15030205 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 mRNA]; naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 mRNA]; naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
naringenin results in increased expression of ARHGDIA mRNA; naringenin results in increased expression of ARHGDIA protein |
CTD |
PMID:27838343 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ARNT protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]] |
CTD |
PMID:20450880 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of ATM mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ATM mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of ATR mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ATR mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Bace1 |
beta-secretase 1 |
decreases activity |
ISO |
naringenin results in decreased activity of BACE1 protein |
CTD |
PMID:31194956 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
naringenin results in increased expression of BAK1 protein |
CTD |
PMID:27838343 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose results in increased expression of BAX mRNA]; naringenin inhibits the reaction [Glucose results in increased expression of BAX protein] [naringenin metabolite co-treated with bisphenol A] results in increased expression of BAX mRNA; naringenin inhibits the reaction [Pyruvaldehyde results in increased expression of BAX protein]; naringenin inhibits the reaction [Tamoxifen results in decreased expression of BAX mRNA]; Tamoxifen promotes the reaction [naringenin results in decreased expression of BAX mRNA] |
CTD |
PMID:23192364 PMID:30153467 PMID:31254498 PMID:36235125 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of BBC3 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BBC3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein] |
CTD |
PMID:23085349 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
[naringenin co-treated with bisphenol A] results in increased expression of BCL2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BCL2 mRNA; ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate inhibits the reaction [BCL2 protein results in decreased susceptibility to naringenin]; naringenin inhibits the reaction [Pyruvaldehyde results in decreased expression of BCL2 protein]; naringenin promotes the reaction [Tamoxifen results in decreased expression of BCL2 mRNA] naringenin results in decreased expression of BCL2 mRNA naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 mRNA]; naringenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:19124070 PMID:23192364 PMID:30153467 PMID:31254498 PMID:36235125 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of BCL2A1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of BCL2A1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BCL2A1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
naringenin results in decreased expression of BCL2L1 protein |
CTD |
PMID:27838343 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
EXP |
naringenin inhibits the reaction [Paraquat results in decreased expression of BDNF mRNA] naringenin results in increased expression of BDNF mRNA |
CTD |
PMID:34655599 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of BIRC5 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BIRC5 mRNA naringenin metabolite results in increased expression of BIRC5 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of BRCA1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BRCA1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of BRCA2 mRNA [naringenin co-treated with bisphenol A] results in increased expression of BRCA2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BRCA2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression multiple interactions |
ISO |
naringenin metabolite results in decreased expression of BTG2 mRNA [naringenin co-treated with bisphenol A] results in increased expression of BTG2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of BTG2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Casp2 |
caspase 2 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CASP2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CASP2 mRNA naringenin results in increased expression of CASP2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression multiple interactions |
ISO EXP |
naringenin results in increased activity of CASP3 protein naringenin results in increased expression of CASP3 mRNA naringenin inhibits the reaction [Pyruvaldehyde results in increased activity of CASP3 protein] naringenin results in increased expression of CASP3 protein modified form naringenin inhibits the reaction [Glucose results in increased activity of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP3 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP3 mRNA]; naringenin inhibits the reaction [methylmercuric chloride results in increased expression of CASP3 protein]; naringenin inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA] |
CTD |
PMID:19124070 PMID:22692793 PMID:23192364 PMID:27838343 PMID:31254498 PMID:34655599 PMID:38308452 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
naringenin results in increased expression of CASP7 protein modified form |
CTD |
PMID:27838343 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions increases expression |
ISO EXP |
naringenin results in increased activity of CASP9 protein [naringenin co-treated with bisphenol A] results in increased expression of CASP9 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CASP9 mRNA; naringenin inhibits the reaction [Pyruvaldehyde results in increased activity of CASP9 protein] naringenin metabolite results in increased expression of CASP9 mRNA; naringenin results in increased expression of CASP9 mRNA; naringenin results in increased expression of CASP9 protein modified form naringenin inhibits the reaction [Glucose results in increased expression of and results in increased cleavage of CASP9 protein]; naringenin inhibits the reaction [Glucose results in increased expression of CASP9 mRNA] |
CTD |
PMID:19124070 PMID:23192364 PMID:27838343 PMID:31254498 PMID:36235125 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases expression increases activity |
EXP ISO |
naringenin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]; naringenin inhibits the reaction [Benzo(a)pyrene results in decreased activity of CAT protein]; naringenin inhibits the reaction [Cadmium Chloride results in decreased expression of CAT protein]; naringenin inhibits the reaction [Cadmium results in decreased activity of CAT protein]; naringenin inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; naringenin inhibits the reaction [Glucose results in decreased activity of CAT protein]; naringenin inhibits the reaction [lead acetate results in decreased activity of CAT protein]; naringenin inhibits the reaction [Paraquat results in increased activity of CAT protein]; naringenin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] naringenin inhibits the reaction [Trichloroethylene results in decreased activity of CAT protein] naringenin results in decreased expression of CAT protein naringenin analog results in increased activity of CAT protein; naringenin results in increased activity of CAT protein naringenin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] |
CTD |
PMID:19063931 PMID:19409769 PMID:23192364 PMID:23283742 PMID:23845967 PMID:25855085 PMID:27206700 PMID:27417253 PMID:28395574 PMID:29223569 PMID:30372826 PMID:34655599 PMID:36807407 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of CCNB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
[Tamoxifen co-treated with naringenin] results in decreased expression of CCND1 mRNA naringenin results in decreased expression of CCND1 mRNA |
CTD |
PMID:30153467 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression multiple interactions |
ISO |
naringenin results in decreased expression of CCNE1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of CCNE1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CCNE1 mRNA; [Tamoxifen co-treated with naringenin] results in decreased expression of CCNE1 mRNA |
CTD |
PMID:30153467 PMID:36235125 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in decreased expression of CCNG1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccnh |
cyclin H |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of CCNH mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:15,835,064...15,855,648
Ensembl chr 2:15,834,833...15,855,819
|
|
G |
Cdc25a |
cell division cycle 25A |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDC25A mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDC25A mRNA naringenin metabolite results in increased expression of CDC25A mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDC25C mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDC25C mRNA |
CTD |
PMID:36235125 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in decreased expression of CDK1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDK1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDK4 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDKN1A mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CDKN1A mRNA; [Tamoxifen co-treated with naringenin] results in increased expression of CDKN1A mRNA naringenin metabolite results in increased expression of CDKN1A mRNA; naringenin results in increased expression of CDKN1A mRNA |
CTD |
PMID:30153467 PMID:36235125 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CDKN2A mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR mRNA]; naringenin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CHEK1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CHEK1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CHEK2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CHEK2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
naringenin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of CRADD mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of CRADD mRNA naringenin results in increased expression of CRADD mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:29,940,240...29,952,907
Ensembl chr 7:29,798,586...29,952,907
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of CTNNB1 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of CTNNB1 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of CTSD mRNA |
CTD |
PMID:24586459 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions increases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose affects the localization of CYCS protein] naringenin results in increased expression of CYCS protein |
CTD |
PMID:23192364 PMID:27838343 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO EXP |
naringenin binds to and results in decreased activity of CYP19A1 protein naringenin results in decreased activity of CYP19A1 protein |
CTD |
PMID:9435150 PMID:15319488 PMID:17895526 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity increases expression |
ISO EXP |
naringenin binds to and results in decreased activity of CYP1A1 protein; naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] naringenin results in decreased activity of CYP1A1 protein naringenin results in increased expression of CYP1A1 mRNA naringenin promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:11454723 PMID:20930378 PMID:21053930 PMID:27444380 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
naringenin results in decreased activity of CYP1A2 protein |
CTD |
PMID:21053930 PMID:29753067 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
naringenin binds to and results in decreased activity of CYP1B1 protein naringenin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21053930 PMID:31621310 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
naringenin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO EXP |
naringenin results in decreased activity of CYP2E1 protein |
CTD |
PMID:33007396 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
naringenin results in decreased activity of CYP3A4 protein naringenin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:19148864 PMID:21053930 PMID:29753067 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of DNMT1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of DNMT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of DRD2 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of DRD2 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of E2F1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of E2F1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of E2F3 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of E2F3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of EGFR mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of EGFR mRNA; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of EGFR protein] |
CTD |
PMID:25866363 PMID:36235125 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of EGR1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of EGR1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Esr1 |
estrogen receptor 1 |
affects activity increases expression decreases expression affects binding increases activity multiple interactions |
ISO EXP |
naringenin affects the activity of ESR1 protein naringenin metabolite results in increased expression of ESR1 mRNA; naringenin results in increased expression of ESR1 mRNA naringenin results in decreased expression of ESR1 mRNA; naringenin results in decreased expression of ESR1 mRNA alternative form; naringenin results in decreased expression of ESR1 protein alternative form naringenin binds to ESR1 protein naringenin results in increased activity of ESR1 protein [naringenin binds to ESR1 protein] which results in increased activity of ALPL protein; [naringenin co-treated with bisphenol A] results in increased expression of ESR1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of ESR1 mRNA; [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of CTSD mRNA; [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PGR mRNA; [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PSEN2 mRNA; [SB 203580 co-treated with naringenin] results in increased degradation of ESR1 protein; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 mRNA; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 mRNA alternative form; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 protein; [Tamoxifen co-treated with naringenin] results in decreased expression of ESR1 protein alternative form; Fulvestrant inhibits the reaction [[naringenin binds to ESR1 protein] which results in increased activity of ALPL protein]; naringenin binds to and results in increased activity of ESR1 protein; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Estradiol results in decreased expression of ESR1 protein]; naringenin promotes the reaction [ESR1 protein binds to ESR1 protein]; naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein |
CTD |
PMID:9751507 PMID:10397250 PMID:10854714 PMID:12650720 PMID:15185748 PMID:15713566 PMID:16118406 PMID:19913605 PMID:22692793 PMID:24586459 PMID:30153467 PMID:36235125 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression increases activity affects binding |
ISO EXP |
[Tamoxifen co-treated with naringenin] results in increased expression of ESR2 mRNA; [Tamoxifen co-treated with naringenin] results in increased expression of ESR2 protein; bisphenol A inhibits the reaction [naringenin metabolite results in increased expression of ESR2 mRNA]; bisphenol A inhibits the reaction [naringenin results in increased expression of ESR2 mRNA]; naringenin binds to and results in increased activity of ESR2 protein; naringenin inhibits the reaction [Estradiol binds to ESR2 protein] naringenin metabolite results in increased expression of ESR2 mRNA; naringenin results in increased expression of ESR2 mRNA; naringenin results in increased expression of ESR2 protein naringenin results in increased activity of ESR2 protein naringenin binds to ESR2 protein |
CTD |
PMID:9751507 PMID:12224631 PMID:16118406 PMID:16566672 PMID:17716812 PMID:19913605 PMID:30153467 PMID:36235125 More...
|
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of FADD mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of FAS mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of FAS mRNA naringenin metabolite results in increased expression of FAS mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of FASLG mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of FASLG mRNA naringenin metabolite results in increased expression of FASLG mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
naringenin results in increased expression of FOS mRNA |
CTD |
PMID:28395574 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of FOXO3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions decreases activity |
EXP ISO |
[naringenin co-treated with lead acetate] results in decreased activity of G6PD protein; naringenin inhibits the reaction [Cadmium Chloride results in decreased expression of G6PD protein] naringenin results in decreased activity of G6PD protein |
CTD |
PMID:19063931 PMID:25130191 PMID:25228019 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of GADD45A mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of GADD45A mRNA naringenin metabolite results in increased expression of GADD45A mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLC protein] |
CTD |
PMID:31254498 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of GCLM protein NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLM protein] |
CTD |
PMID:31254498 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gml |
glycosylphosphatidylinositol anchored molecule like |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of GML mRNA [naringenin co-treated with bisphenol A] results in increased expression of GML mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of GML mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:106,683,749...106,712,802
Ensembl chr 7:106,689,410...106,712,724
|
|
G |
Gper1 |
G protein-coupled estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
[Tamoxifen co-treated with naringenin] results in decreased expression of GPER1 mRNA; [Tamoxifen co-treated with naringenin] results in decreased expression of GPER1 protein naringenin metabolite results in decreased expression of GPER1 mRNA; naringenin results in decreased expression of GPER1 mRNA; naringenin results in decreased expression of GPER1 protein |
CTD |
PMID:30153467 PMID:36235125 |
|
NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
[naringenin co-treated with methylmercuric chloride] results in decreased activity of GPT protein; naringenin inhibits the reaction [Arsenic Trioxide results in increased activity of GPT protein]; naringenin inhibits the reaction [Streptozocin results in increased activity of GPT protein] |
CTD |
PMID:23283742 PMID:29223569 PMID:38308452 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose results in decreased expression of GPX1 mRNA] naringenin results in decreased expression of GPX1 protein |
CTD |
PMID:23192364 PMID:28395574 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of GPX2 mRNA naringenin results in increased expression of GPX2 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of GPX3 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gpx5 |
glutathione peroxidase 5 |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of GPX5 mRNA [Paraquat co-treated with naringenin] results in increased expression of GPX5 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr17:43,436,126...43,443,074
Ensembl chr17:43,416,340...43,443,074
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of GPX7 mRNA naringenin results in increased expression of GPX7 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
EXP ISO |
naringenin inhibits the reaction [Cadmium Chloride results in decreased expression of GSR protein]; naringenin inhibits the reaction [Glucose results in decreased expression of GSR mRNA] Paraquat inhibits the reaction [naringenin results in increased expression of GSR mRNA] |
CTD |
PMID:19063931 PMID:23192364 PMID:24561720 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
multiple interactions increases expression |
ISO |
Paraquat inhibits the reaction [naringenin results in increased expression of GSTZ1 mRNA] |
CTD |
PMID:24561720 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
naringenin inhibits the reaction [Carbon Tetrachloride results in increased expression of HAVCR1 protein] |
CTD |
PMID:23845967 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hk2 |
hexokinase 2 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of HK2 mRNA [naringenin co-treated with bisphenol A] results in increased expression of HK2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of HK2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringenin results in increased expression of HMOX1 protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of and results in decreased activity of HMOX1 protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of HMOX1 mRNA]; naringenin results in increased expression of and results in increased activity of HMOX1 protein; wortmannin inhibits the reaction [naringenin results in increased expression of HMOX1 protein] naringenin results in increased expression of HMOX1 mRNA; naringenin results in increased expression of HMOX1 protein [Paraquat co-treated with naringenin] results in increased expression of HMOX1 mRNA naringenin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein] |
CTD |
PMID:15316927 PMID:22709785 PMID:24561720 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of IGF1R mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of IGF1R mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases expression |
ISO |
naringenin results in increased expression of IKBKB mRNA |
CTD |
PMID:28395574 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
naringenin inhibits the reaction [lead acetate results in increased expression of IL1B protein] naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:36807407 PMID:37880698 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of IL6 mRNA naringenin inhibits the reaction [tyloxapol results in increased expression of IL6 mRNA] [naringenin co-treated with bisphenol A] results in increased expression of IL6 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of IL6 mRNA |
CTD |
PMID:36235125 PMID:37076581 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
EXP |
naringenin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]; naringenin inhibits the reaction [ITGA4 protein results in increased expression of TEK protein]; naringenin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
ISO |
naringenin metabolite results in decreased expression of JUN mRNA; naringenin results in decreased expression of JUN mRNA naringenin results in increased expression of JUN mRNA |
CTD |
PMID:28395574 PMID:36235125 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of KAT2B mRNA [naringenin co-treated with bisphenol A] results in increased expression of KAT2B mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of KAT2B mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Amiodarone promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; azimilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; dofetilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [Amiodarone results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [azimilide results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [dofetilide results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [Quinidine results in decreased activity of KCNH2 protein]; Quinidine promotes the reaction [naringenin results in decreased activity of KCNH2 protein] |
CTD |
PMID:18057881 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
EXP |
naringenin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein] |
CTD |
PMID:36731809 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of KRAS mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
naringenin inhibits the reaction [lead acetate results in decreased expression of LHB protein] |
CTD |
PMID:36807407 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpo |
lactoperoxidase |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of LPO mRNA Paraquat inhibits the reaction [naringenin results in increased expression of LPO mRNA] |
CTD |
PMID:24561720 |
|
NCBI chr10:72,606,950...72,626,220
Ensembl chr10:72,606,944...72,626,535
|
|
G |
Lrrc27 |
leucine rich repeat containing 27 |
increases expression |
ISO |
naringenin results in increased expression of LRRC27 mRNA; naringenin results in increased expression of LRRC27 protein |
CTD |
PMID:27838343 |
|
NCBI chr 1:194,004,967...194,035,087
Ensembl chr 1:194,005,182...194,035,084
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of LRRK2 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of LRRK2 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases expression |
ISO |
naringenin results in increased expression of MAP3K5 protein |
CTD |
PMID:27838343 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases expression decreases activity decreases phosphorylation |
EXP ISO |
naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] naringenin results in decreased expression of MAPK1 mRNA naringenin results in decreased activity of MAPK1 protein naringenin results in decreased phosphorylation of MAPK1 protein naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20450880 PMID:22709785 PMID:25866363 PMID:27468969 PMID:30431227 PMID:36819991 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases activity decreases phosphorylation |
EXP ISO |
naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] naringenin results in decreased activity of MAPK3 protein naringenin results in decreased phosphorylation of MAPK3 protein naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] naringenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20450880 PMID:22709785 PMID:25866363 PMID:27468969 PMID:30431227 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
naringenin results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:27838343 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
naringenin results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:27838343 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of MCL1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MCL1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdk |
midkine |
multiple interactions |
EXP |
naringenin inhibits the reaction [MDK protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of MDM2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MDM2 mRNA naringenin metabolite results in increased expression of MDM2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of MDM4 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MDM4 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
|
|
G |
Mir141 |
microRNA 141 |
decreases expression |
ISO |
naringenin metabolite results in decreased expression of MIR141 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir200c |
microRNA 200c |
multiple interactions |
ISO |
naringenin inhibits the reaction [bisphenol A results in increased expression of MIR200C mRNA]; naringenin metabolite inhibits the reaction [bisphenol A results in increased expression of MIR200C mRNA] |
CTD |
PMID:36235125 |
|
NCBI chr 4:157,523,679...157,523,747
|
|
G |
Mlh1 |
mutL homolog 1 |
increases expression multiple interactions |
ISO |
naringenin results in increased expression of MLH1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of MLH1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MLH1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression multiple interactions |
ISO |
naringenin results in decreased expression of MMP2 mRNA naringenin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:30153467 PMID:30431227 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased secretion of MMP9 protein]; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; naringenin results in decreased expression of and results in decreased activity of MMP9 protein naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein] naringenin results in decreased expression of MMP9 mRNA |
CTD |
PMID:25866363 PMID:30153467 PMID:30431227 PMID:37880698 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msh2 |
mutS homolog 2 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of MSH2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
naringenin inhibits the reaction [lead acetate results in decreased expression of MTOR protein] |
CTD |
PMID:36807407 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myod1 |
myogenic differentiation 1 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of MYOD1 mRNA; naringenin results in increased expression of MYOD1 mRNA [naringenin co-treated with bisphenol A] results in increased expression of MYOD1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of MYOD1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
naringenin results in decreased expression of NANOG protein |
CTD |
PMID:27468969 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of NF1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of NF1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases activity increases expression |
ISO |
[naringenin co-treated with Paraquat] results in increased expression of NFE2L2 protein; naringenin results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [naringenin results in increased expression of GCLM protein] naringenin results in increased activity of NFE2L2 protein naringenin results in increased expression of NFE2L2 mRNA |
CTD |
PMID:24561720 PMID:31254498 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of NFKB1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of NFKB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
naringenin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:10188978 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbil1 |
NFKB inhibitor like 1 |
increases expression |
ISO |
naringenin results in increased expression of NFKBIL1 mRNA; naringenin results in increased expression of NFKBIL1 protein |
CTD |
PMID:27838343 |
|
NCBI chr20:3,589,974...3,608,348
Ensembl chr20:3,590,642...3,605,616
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
increases expression |
ISO |
naringenin results in increased expression of NME1 mRNA; naringenin results in increased expression of NME1 protein |
CTD |
PMID:27838343 |
|
NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; naringenin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:10188978 PMID:12512693 PMID:15316927 PMID:18274639 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with naringenin] results in increased expression of NQO1 mRNA naringenin results in increased expression of NQO1 mRNA; naringenin results in increased expression of NQO1 protein |
CTD |
PMID:24561720 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
naringenin results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
naringenin results in increased cleavage of PARP1 protein naringenin inhibits the reaction [Pyruvaldehyde results in increased cleavage of PARP1 protein] |
CTD |
PMID:27838343 PMID:31254498 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PCNA mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PCNA mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
naringenin results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
EXP ISO |
naringenin results in increased expression of PGR mRNA [naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PGR mRNA |
CTD |
PMID:10397250 PMID:24586459 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PIDD1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PIDD1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression |
ISO |
naringenin results in increased expression of PON1 mRNA |
CTD |
PMID:15169886 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARA protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARA protein] naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in decreased expression of PPARA protein] |
CTD |
PMID:31063766 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in decreased expression of PPARB protein] HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARB protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARB protein] |
CTD |
PMID:31063766 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
HET0016 inhibits the reaction [naringenin inhibits the reaction [Glucose results in decreased expression of PPARG protein]]; naringenin inhibits the reaction [Glucose results in decreased expression of PPARG protein]; naringenin inhibits the reaction [Streptozocin results in decreased expression of PPARG mRNA]; naringenin inhibits the reaction [Streptozocin results in decreased expression of PPARG protein] naringenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Carboxymethylcellulose Sodium] results in decreased expression of PPARG protein] |
CTD |
PMID:29223569 PMID:31063766 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PPM1D mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PPM1D mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Prdx1 |
peroxiredoxin 1 |
decreases expression |
ISO |
naringenin results in decreased expression of PRDX1 mRNA; naringenin results in decreased expression of PRDX1 protein |
CTD |
PMID:27838343 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of PRKCA mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of PRKCA mRNA; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein] |
CTD |
PMID:25866363 PMID:36235125 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
naringenin inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCB protein] |
CTD |
PMID:25866363 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcg |
protein kinase C, gamma |
multiple interactions |
ISO |
naringenin inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCG protein] |
CTD |
PMID:25866363 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prom1 |
prominin 1 |
decreases expression |
ISO |
naringenin results in decreased expression of PROM1 protein |
CTD |
PMID:27468969 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Psen2 |
presenilin 2 |
multiple interactions |
ISO |
[naringenin results in increased phosphorylation of and results in increased activity of ESR1 protein] which results in increased expression of PSEN2 mRNA |
CTD |
PMID:24586459 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of PTEN mRNA naringenin results in increased expression of PTEN mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
naringenin results in increased expression of PTGS1 mRNA |
CTD |
PMID:24561720 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] naringenin inhibits the reaction [Trichloroethylene results in increased expression of PTGS2 protein] naringenin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:21341175 PMID:25855085 PMID:27206700 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of PTTG1 mRNA [naringenin metabolite co-treated with bisphenol A] results in increased expression of PTTG1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of RB1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein] naringenin inhibits the reaction [Trichloroethylene results in increased expression of RELA protein] naringenin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein]; naringenin inhibits the reaction [MDK protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:18274639 PMID:25855085 PMID:27206700 PMID:36731809 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rprm |
reprimo, TP53 dependent G2 arrest mediator homolog |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of RPRM mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of RPRM mRNA naringenin metabolite results in increased expression of RPRM mRNA; naringenin results in increased expression of RPRM mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:38,539,581...38,540,998
Ensembl chr 3:38,539,581...38,540,998
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
increases expression |
ISO |
naringenin results in increased expression of RPTOR mRNA; naringenin results in increased expression of RPTOR protein |
CTD |
PMID:27838343 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
naringenin inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:22709785 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of SESN2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of SESN2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
naringenin binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Si |
sucrase-isomaltase |
decreases activity multiple interactions |
EXP ISO |
naringenin results in decreased activity of SI protein naringenin binds to and results in decreased activity of SI protein |
CTD |
PMID:24412302 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Siah1 |
siah E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of SIAH1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr19:20,378,908...20,402,512
Ensembl chr19:20,378,439...20,403,808
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of SIRT1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of SIRT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [SLC16A1 protein results in increased uptake of Benzoic Acid] [naringenin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 PMID:17976262 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions decreases activity |
ISO |
naringenin inhibits the reaction [SLC2A1 protein affects the transport of Glucose] naringenin results in decreased activity of SLC2A1 protein |
CTD |
PMID:14642735 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
naringenin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 mRNA]; naringenin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:29223569 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
ISO |
naringenin inhibits the reaction [SLC5A1 protein results in increased uptake of methylglucoside] |
CTD |
PMID:17495124 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
decreases expression multiple interactions |
EXP |
naringenin results in decreased expression of SLC6A3 mRNA naringenin inhibits the reaction [Paraquat results in decreased expression of SLC6A3 mRNA] |
CTD |
PMID:34655599 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
naringenin inhibits the reaction [SLCO1B3 protein results in increased import of Sulfobromophthalein] |
CTD |
PMID:22394605 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
naringenin results in decreased expression of SNAI1 protein |
CTD |
PMID:30431227 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression |
ISO |
naringenin results in decreased expression of SNAI2 protein |
CTD |
PMID:30431227 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases expression |
EXP |
naringenin inhibits the reaction [Paraquat results in increased expression of SNCA mRNA] naringenin results in increased expression of SNCA mRNA |
CTD |
PMID:34655599 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
naringenin results in increased expression of SOCS3 mRNA |
CTD |
PMID:23782265 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP ISO |
naringenin inhibits the reaction [Glucose results in increased expression of SOD1 mRNA] naringenin results in decreased expression of SOD1 protein |
CTD |
PMID:23192364 PMID:28395574 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
naringenin inhibits the reaction [Glucose results in decreased expression of SOD2 mRNA] |
CTD |
PMID:23192364 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
naringenin results in decreased expression of SOX2 protein |
CTD |
PMID:27468969 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
naringenin inhibits the reaction [TNF protein results in increased expression of SPP1 mRNA] |
CTD |
PMID:22709785 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in decreased expression of STAT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
naringenin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:27468969 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO EXP |
Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of naringenin] |
CTD |
PMID:11181495 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Tada3 |
transcriptional adaptor 3 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in decreased expression of TADA3 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 4:146,510,213...146,521,975
Ensembl chr 4:146,510,246...146,521,590
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions |
EXP |
naringenin inhibits the reaction [ITGA4 protein results in increased expression of TEK protein] |
CTD |
PMID:36731809 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] naringenin inhibits the reaction [lead acetate results in increased expression of TGFB1 protein] |
CTD |
PMID:23845967 PMID:36807407 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions decreases expression |
EXP |
naringenin inhibits the reaction [Paraquat results in decreased expression of TH protein] naringenin results in decreased expression of TH protein |
CTD |
PMID:34655599 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression decreases activity |
ISO EXP |
[naringenin co-treated with bisphenol A] results in increased expression of TNF mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TNF mRNA; naringenin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein] naringenin metabolite results in increased expression of TNF mRNA naringenin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; naringenin inhibits the reaction [tyloxapol results in increased expression of TNF mRNA] naringenin results in decreased activity of TNF protein naringenin inhibits the reaction [lead acetate results in increased expression of TNF protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of and results in decreased activity of HMOX1 protein]; naringenin inhibits the reaction [TNF protein results in decreased expression of HMOX1 mRNA]; naringenin inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; naringenin inhibits the reaction [TNF protein results in increased expression of SPP1 mRNA]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; naringenin inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin inhibits the reaction [naringenin results in decreased activity of TNF protein] |
CTD |
PMID:18720166 PMID:19135038 PMID:22709785 PMID:36235125 PMID:36807407 PMID:37076581 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
[Tamoxifen co-treated with naringenin] results in increased expression of TP53 mRNA; naringenin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of TP53 protein]; naringenin results in increased expression of and results in increased phosphorylation of TP53 protein naringenin results in increased expression of TP53 mRNA |
CTD |
PMID:15795422 PMID:27838343 PMID:30153467 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53bp2 |
tumor protein p53 binding protein, 2 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in increased expression of TP53BP2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr13:94,088,769...94,145,436
Ensembl chr13:94,088,709...94,145,432
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of TP63 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TP63 mRNA naringenin metabolite results in increased expression of TP63 mRNA; naringenin results in increased expression of TP63 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398
|
|
G |
Tp73 |
tumor protein p73 |
increases expression multiple interactions |
ISO |
naringenin metabolite results in increased expression of TP73 mRNA; naringenin results in increased expression of TP73 mRNA [naringenin co-treated with bisphenol A] results in increased expression of TP73 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TP73 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Tpo |
thyroid peroxidase |
decreases activity |
EXP |
naringenin results in decreased activity of TPO protein |
CTD |
PMID:26884060 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of TRAF2 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of TRAF2 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Tsc1 |
TSC complex subunit 1 |
multiple interactions |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of TSC1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:11,969,547...12,018,591
Ensembl chr 3:11,979,729...12,015,674
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
EXP |
naringenin inhibits the reaction [Dietary Fats results in decreased expression of UCP1 mRNA] |
CTD |
PMID:30372826 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation increases expression |
ISO |
UGT1A1 protein results in increased glucuronidation of naringenin naringenin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:14557274 PMID:31621310 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of naringenin |
CTD |
PMID:14557274 PMID:18816295 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
increases metabolic processing |
EXP |
UGT2B15 protein results in increased metabolism of naringenin |
CTD |
PMID:7574722 |
|
NCBI chr14:20,768,015...20,783,599
Ensembl chr14:20,768,015...20,783,589
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO EXP |
naringenin inhibits the reaction [tyloxapol results in increased expression of VEGFA mRNA] naringenin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 PMID:37076581 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions increases expression |
ISO |
[naringenin co-treated with bisphenol A] results in increased expression of WT1 mRNA; [naringenin metabolite co-treated with bisphenol A] results in increased expression of WT1 mRNA naringenin metabolite results in increased expression of WT1 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
naringenin inhibits the reaction [Benzo(a)pyrene results in increased activity of XDH protein] |
CTD |
PMID:27206700 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
multiple interactions |
ISO |
[naringenin metabolite co-treated with bisphenol A] results in decreased expression of XRCC5 mRNA |
CTD |
PMID:36235125 |
|
NCBI chr 9:73,955,216...74,044,020
Ensembl chr 9:73,955,216...74,044,018
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
6-prenylnaringenin results in increased expression of CYP1A1 mRNA; 6-prenylnaringenin results in increased expression of CYP1A1 protein 6-prenylnaringenin inhibits the reaction [DNMT1 protein binds to CYP1A1 promoter]; 6-prenylnaringenin inhibits the reaction [Estradiol promotes the reaction [DNMT1 protein binds to CYP1A1 promoter]]; 6-prenylnaringenin inhibits the reaction [Estradiol results in decreased expression of CYP1A1 mRNA] |
CTD |
PMID:27269377 PMID:32986415 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
6-prenylnaringenin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:27269377 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
6-prenylnaringenin inhibits the reaction [DNMT1 protein binds to CYP1A1 promoter]; 6-prenylnaringenin inhibits the reaction [Estradiol promotes the reaction [DNMT1 protein binds to CYP1A1 promoter]] |
CTD |
PMID:32986415 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [6-prenylnaringenin results in decreased expression of ESR1 protein]; 6-prenylnaringenin promotes the reaction [Estradiol results in decreased expression of ESR1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [6-prenylnaringenin results in decreased expression of ESR1 protein] |
CTD |
PMID:32986415 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
naringin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] |
CTD |
PMID:34217736 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[naringin co-treated with Dietary Fats] results in decreased expression of ACACA mRNA |
CTD |
PMID:22198281 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ACE protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACE protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of ACE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of ACE protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACE protein] |
CTD |
PMID:32172062 PMID:32810514 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of ACHE protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in increased expression of ACHE protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ACHE protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of ACHE protein]; naringin inhibits the reaction [[potassium bromate co-treated with Caffeine] results in increased activity of ACHE protein]; naringin inhibits the reaction [bisphenol A results in increased activity of ACHE protein]; naringin inhibits the reaction [Caffeine results in increased activity of ACHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of ACHE protein]; naringin inhibits the reaction [potassium bromate results in increased activity of ACHE protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 PMID:37865952 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions decreases expression |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [Polymethyl Methacrylate analog results in increased expression of and results in increased activity of ACP5 protein] naringin results in decreased expression of ACP5 mRNA |
CTD |
PMID:21835177 PMID:24376342 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of ADA protein]; naringin inhibits the reaction [[potassium bromate co-treated with Caffeine] results in increased activity of ADA protein]; naringin inhibits the reaction [bisphenol A results in increased activity of ADA protein]; naringin inhibits the reaction [Caffeine results in increased activity of ADA protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ADA protein]; naringin inhibits the reaction [potassium bromate results in increased activity of ADA protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 PMID:37865952 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] |
CTD |
PMID:22198281 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
naringin inhibits the reaction [AGT protein results in increased expression of CYP11B2 mRNA]; naringin inhibits the reaction [AGT protein results in increased secretion of Aldosterone] |
CTD |
PMID:22798349 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
naringin inhibits the reaction [Acetaminophen results in decreased expression of AKR7A5 protein] |
CTD |
PMID:35166444 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Methylprednisolone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; plerixafor inhibits the reaction [naringin results in increased phosphorylation of AKT1 protein] naringin inhibits the reaction [Dexamethasone results in decreased phosphorylation of AKT1 protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of AKT1 mRNA] |
CTD |
PMID:19810018 PMID:25773745 PMID:29510123 PMID:30878453 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt1 |
angiopoietin 1 |
affects expression |
EXP |
naringin affects the expression of ANGPT1 mRNA |
CTD |
PMID:24880026 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP1 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of AQP5 protein] |
CTD |
PMID:31301536 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of ATF6 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAD mRNA] naringin inhibits the reaction [Dexamethasone results in increased phosphorylation of BAD protein] |
CTD |
PMID:21945202 PMID:30878453 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of BAX mRNA CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]]; naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of BAX protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of BAX protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]] naringin inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of BAX mRNA]; naringin inhibits the reaction [Acrylamide results in increased expression of BAX protein]; naringin inhibits the reaction [Oxaliplatin results in increased expression of BAX mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of BAX protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of BAX mRNA] |
CTD |
PMID:21945202 PMID:22847135 PMID:28422390 PMID:30130594 PMID:30878453 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of BCHE protein]; naringin inhibits the reaction [bisphenol A results in increased activity of BCHE protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of BCHE protein] |
CTD |
PMID:32172062 PMID:32810514 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
[naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [Oxaliplatin results in decreased expression of BCL2 mRNA]; naringin inhibits the reaction [Oxaliplatin results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Quinolinic Acid results in decreased expression of BCL2 mRNA] naringin results in decreased expression of BCL2 protein CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]]; naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Dexamethasone results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]] naringin inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] |
CTD |
PMID:21945202 PMID:28422390 PMID:30130594 PMID:30878453 PMID:35166444 PMID:35179299 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression increases secretion multiple interactions |
ISO EXP |
naringin results in increased expression of BGLAP mRNA; naringin results in increased expression of BGLAP protein naringin results in increased secretion of BGLAP protein fulvestrant inhibits the reaction [naringin results in increased secretion of BGLAP protein] |
CTD |
PMID:18495116 PMID:21741227 PMID:23596885 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions decreases expression increases secretion increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [FOS protein binds to BMP2 promoter]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [JUN protein binds to BMP2 promoter]]; FOS protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; FOS protein affects the reaction [naringin results in increased expression of BMP2 protein]; JUN protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; JUN protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin promotes the reaction [FOS protein binds to BMP2 promoter]; naringin promotes the reaction [JUN protein binds to BMP2 promoter] naringin results in decreased expression of BMP2 mRNA fulvestrant inhibits the reaction [naringin results in increased secretion of BMP2 protein] naringin results in increased expression of BMP2 mRNA; naringin results in increased expression of BMP2 protein |
CTD |
PMID:18495116 PMID:21820093 PMID:23596885 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp3 |
bone morphogenetic protein 3 |
decreases expression |
ISO |
naringin results in decreased expression of BMP3 mRNA |
CTD |
PMID:18495116 |
|
NCBI chr14:10,712,489...10,737,153
Ensembl chr14:10,712,489...10,737,153
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
increases expression |
ISO |
naringin results in increased expression of BMP4 mRNA |
CTD |
PMID:24915843 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Calcr |
calcitonin receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of CASP3 mRNA naringin inhibits the reaction [Acetaminophen results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein modified form]; naringin inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein]; naringin inhibits the reaction [Dexamethasone results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of CASP3 protein] naringin inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]]; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased cleavage of CASP3 protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]; naringin inhibits the reaction [Acrylamide results in increased expression of CASP3 protein]; naringin inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of CASP3 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of CASP3 protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of CASP3 mRNA]; rottlerin inhibits the reaction [naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP3 protein]] |
CTD |
PMID:21945202 PMID:22847135 PMID:25773745 PMID:26612654 PMID:28422390 PMID:30130594 PMID:30878453 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of CASP9 mRNA [bisphenol A co-treated with naringin] results in decreased expression of CASP9 protein; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in decreased expression of CASP9 protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of CASP9 protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased cleavage of and results in increased activity of CASP9 protein]; naringin inhibits the reaction [bisphenol A results in increased expression of CASP9 protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of CASP9 protein] |
CTD |
PMID:22847135 PMID:25773745 PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of CAT protein]; naringin inhibits the reaction [Ferric Compounds results in decreased activity of CAT protein]; naringin inhibits the reaction [Nanotubes, Carbon results in decreased activity of CAT protein] naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]; naringin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased activity of CAT protein]; naringin inhibits the reaction [Acrylamide results in decreased activity of CAT protein]; naringin inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; naringin inhibits the reaction [Cisplatin results in increased expression of CAT protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; naringin inhibits the reaction [nickel sulfate results in decreased activity of CAT protein]; naringin inhibits the reaction [Oxaliplatin results in decreased activity of CAT protein] |
CTD |
PMID:20950607 PMID:21345335 PMID:21945202 PMID:22198281 PMID:25773745 PMID:26120027 PMID:26612654 PMID:29658312 PMID:33992719 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] naringin inhibits the reaction [Cyclophosphamide results in increased expression of CCL2 mRNA] |
CTD |
PMID:22965302 PMID:33992719 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL3 mRNA]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] |
CTD |
PMID:22965302 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein] |
CTD |
PMID:21500970 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions increases expression |
ISO EXP |
naringin results in decreased expression of CCND1 protein naringin inhibits the reaction [Dexamethasone results in increased expression of CCND1 mRNA] naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CCND1 protein] naringin results in increased expression of CCND1 mRNA |
CTD |
PMID:18296682 PMID:18951945 PMID:24915843 PMID:26482937 PMID:30878453 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO EXP |
naringin results in decreased expression of CCNE1 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in decreased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK2 protein]; naringin results in decreased expression of and results in decreased activity of CDK2 protein; RAF1 protein affects the reaction [naringin results in decreased expression of CDK2 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; naringin results in decreased expression of and results in decreased activity of CDK2 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; naringin results in decreased expression of and results in decreased activity of CDK4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in decreased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; naringin results in decreased expression of and results in decreased activity of CDK4 protein; RAF1 protein affects the reaction [naringin results in decreased expression of CDK4 protein] |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein] naringin results in increased expression of CDKN1A mRNA; naringin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; naringin promotes the reaction [CDKN1A protein binds to CDK2 protein]; naringin promotes the reaction [CDKN1A protein binds to CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein] |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR mRNA]; naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of CFTR protein] |
CTD |
PMID:31301536 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chac2 |
ChaC glutathione specific gamma-glutamylcyclotransferase 2 |
multiple interactions |
ISO |
CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]]; CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]]; CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]]; naringin inhibits the reaction [Acetaminophen results in decreased expression of CHAC2 protein] |
CTD |
PMID:35166444 PMID:35179299 |
|
NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
naringin results in increased expression of COL1A1 mRNA |
CTD |
PMID:21741227 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Dietary Fats co-treated with naringin] results in decreased expression of CPT1A mRNA |
CTD |
PMID:22198281 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA] |
CTD |
PMID:21835177 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
naringin results in increased expression of CTNNB1 mRNA naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CTNNB1 protein] |
CTD |
PMID:24915843 PMID:26482937 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of CTSB protein]; naringin inhibits the reaction [Isoproterenol results in increased activity of CTSB protein] |
CTD |
PMID:17188415 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:17188415 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions decreases expression |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA] naringin results in decreased expression of CTSK mRNA |
CTD |
PMID:21835177 PMID:24376342 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
EXP |
naringin results in increased expression of CXCL12 protein |
CTD |
PMID:29510123 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
affects expression |
ISO |
naringin affects the expression of CXCL2 mRNA |
CTD |
PMID:25117567 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
EXP |
naringin results in increased expression of CXCR4 protein |
CTD |
PMID:29510123 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
naringin inhibits the reaction [TNF protein results in increased expression of CYBA mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA protein] |
CTD |
PMID:25391245 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
naringin inhibits the reaction [Cadmium Chloride results in increased expression of CYCS protein] |
CTD |
PMID:28422390 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [AGT protein results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:22798349 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:36598108 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
naringin results in decreased activity of CYP1A1 protein |
CTD |
PMID:21053930 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
naringin results in decreased activity of CYP1A2 protein |
CTD |
PMID:21053930 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
naringin binds to and results in decreased activity of CYP1B1 protein |
CTD |
PMID:21053930 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
ISO |
naringin results in decreased activity of CYP3A4 protein naringin inhibits the reaction [CYP3A4 protein affects the metabolism of Verapamil] |
CTD |
PMID:16013069 PMID:21053930 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases activity |
ISO |
naringin results in decreased activity of DHFR protein |
CTD |
PMID:25418905 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]] |
CTD |
PMID:26482937 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
naringin inhibits the reaction [EGF protein affects the localization of RELA protein]; naringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein]; naringin inhibits the reaction [EGF protein results in increased expression of MUC5AC mRNA]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
naringin inhibits the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein] |
CTD |
PMID:22766066 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of ERN1 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [naringin results in increased expression of ESR1 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [naringin results in increased expression of ESR2 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
naringin results in increased expression of FADD mRNA |
CTD |
PMID:22847135 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
naringin results in increased expression of FAS mRNA |
CTD |
PMID:22847135 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the activity of FASN protein]; naringin inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:16427799 PMID:22198281 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [naringin results in increased expression of FGF2 mRNA] |
CTD |
PMID:23596885 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [FOS protein binds to BMP2 promoter]]; FOS protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; FOS protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin promotes the reaction [FOS protein binds to BMP2 promoter] naringin results in increased expression of FOS mRNA |
CTD |
PMID:18495116 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of FSHB protein] |
CTD |
PMID:36598108 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of G6PC1 mRNA]; naringin inhibits the reaction [Dietary Fats results in increased expression of G6PC1 mRNA] |
CTD |
PMID:16427799 PMID:22198281 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [nickel sulfate results in decreased activity of G6PD protein] naringin affects the reaction [LEPR protein affects the activity of G6PD protein] |
CTD |
PMID:16427799 PMID:20950607 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased activity of GAL protein] |
CTD |
PMID:17188415 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of GCK mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of GCLC protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of GCLC protein]; [naringin co-treated with 3-nitropropionic acid] results in increased expression of GCLC mRNA; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of GCLC protein]; rottlerin inhibits the reaction [naringin results in increased expression of GCLC protein] naringin results in increased expression of GCLC mRNA; naringin results in increased expression of GCLC protein |
CTD |
PMID:22871521 PMID:25773745 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Acetaminophen results in increased secretion of GOT1 protein] |
CTD |
PMID:35166444 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
naringin affects the reaction [Cyclophosphamide affects the activity of GPT protein]; naringin inhibits the reaction [Oxaliplatin results in increased activity of GPT protein]; naringin inhibits the reaction [sodium arsenite results in increased expression of GPT protein] naringin inhibits the reaction [Acetaminophen results in increased secretion of GPT protein]; naringin inhibits the reaction [Doxorubicin results in increased expression of GPT protein] |
CTD |
PMID:27174133 PMID:33992719 PMID:35166444 PMID:36811345 PMID:38037725 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases activity |
ISO |
naringin results in increased activity of GPX1 protein |
CTD |
PMID:23603004 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [3-nitropropionic acid results in decreased activity of GSR protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; naringin inhibits the reaction [nickel sulfate results in decreased activity of GSR protein] naringin inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:20950607 PMID:21945202 PMID:23650045 PMID:33992719 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
EXP |
naringin results in increased expression of GSTP1 mRNA [naringin co-treated with 3-nitropropionic acid] results in increased expression of GSTP1 mRNA |
CTD |
PMID:22871521 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; naringin inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:17188415 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [Isoproterenol results in increased activity of HMGCR protein] naringin affects the reaction [LEPR protein affects the activity of HMGCR protein] |
CTD |
PMID:16427799 PMID:16906524 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression increases activity |
ISO EXP |
CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]]; naringin inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein]; naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 mRNA]; naringin inhibits the reaction [Paraquat results in decreased expression of HMOX1 protein]; naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]] naringin results in increased expression of HMOX1 mRNA; naringin results in increased expression of HMOX1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of HMOX1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased expression of HMOX1 protein]; [naringin co-treated with 3-nitropropionic acid] results in increased expression of HMOX1 mRNA; naringin inhibits the reaction [Oxaliplatin results in decreased expression of HMOX1 mRNA]; naringin inhibits the reaction [sodium arsenite results in decreased expression of HMOX1 mRNA]; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of HMOX1 protein]; rottlerin inhibits the reaction [naringin results in increased expression of HMOX1 protein] naringin results in increased activity of HMOX1 protein |
CTD |
PMID:22871521 PMID:23603004 PMID:25773745 PMID:27174133 PMID:35166444 PMID:35179299 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions increases activity |
ISO EXP |
HRAS protein affects the reaction [naringin results in decreased expression of CDK2 protein]; HRAS protein affects the reaction [naringin results in decreased expression of CDK4 protein]; HRAS protein affects the reaction [naringin results in increased expression of CDKN1A protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in increased activity of HRAS protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
naringin inhibits the reaction [Oxaliplatin results in increased expression of HSPA5 mRNA] |
CTD |
PMID:38037725 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions affects expression |
ISO |
naringin inhibits the reaction [Glucose results in increased expression of ICAM1]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] naringin inhibits the reaction [Acetaminophen results in increased expression of ICAM1 mRNA] naringin affects the expression of ICAM1 mRNA |
CTD |
PMID:22074828 PMID:25117567 PMID:25391245 PMID:35166444 PMID:35179299 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifna1 |
interferon, alpha 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Cyclophosphamide results in increased expression of IFNA1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Ifng |
interferon gamma |
multiple interactions affects expression |
ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein] naringin affects the expression of IFNG mRNA |
CTD |
PMID:16945185 PMID:21500970 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression multiple interactions increases expression |
EXP ISO |
naringin affects the expression of IGF1 mRNA naringin inhibits the reaction [Dexamethasone results in increased expression of IGF1 mRNA] naringin results in increased expression of IGF1 mRNA fulvestrant inhibits the reaction [naringin results in increased expression of IGF1 mRNA] |
CTD |
PMID:23596885 PMID:24880026 PMID:30878453 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il10 |
interleukin 10 |
multiple interactions affects expression |
EXP ISO |
naringin inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IL10 protein] naringin affects the expression of IL10 protein |
CTD |
PMID:22985397 PMID:25117567 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
affects expression multiple interactions |
EXP ISO |
naringin affects the expression of IL1B mRNA [bisphenol A co-treated with naringin] results in increased expression of IL1B protein; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA]; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of IL1B protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in increased expression of IL1B protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of IL1B protein]; naringin inhibits the reaction [Acrylamide results in increased expression of IL1B protein]; naringin inhibits the reaction [bisphenol A results in increased expression of IL1B protein]; naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of IL1B protein]; naringin inhibits the reaction [Oxaliplatin results in increased expression of IL1B mRNA]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of IL1B mRNA] naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B protein] naringin inhibits the reaction [Acetaminophen results in increased expression of IL1B mRNA]; naringin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA] |
CTD |
PMID:24131540 PMID:24880026 PMID:30130594 PMID:32172062 PMID:32428650 PMID:32810514 PMID:33992719 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1R1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il2 |
interleukin 2 |
affects expression |
ISO |
naringin affects the expression of IL2 protein |
CTD |
PMID:25117567 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
affects expression |
ISO |
naringin affects the expression of IL4 protein |
CTD |
PMID:25117567 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
affects expression multiple interactions decreases expression |
EXP ISO |
naringin affects the expression of IL6 mRNA [naringin co-treated with Hesperidin] results in decreased expression of IL6 protein; [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; naringin inhibits the reaction [Acrylamide results in increased expression of IL6 protein]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of IL6 mRNA]; naringin inhibits the reaction [TNF protein results in increased secretion of IL6 protein] naringin results in decreased expression of IL6 protein naringin affects the expression of IL6 protein naringin inhibits the reaction [Acetaminophen results in increased expression of IL6 mRNA]; naringin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 protein] |
CTD |
PMID:16137700 PMID:19810018 PMID:21820093 PMID:24131540 PMID:24880026 PMID:25117567 PMID:30130594 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions affects expression |
ISO EXP |
naringin inhibits the reaction [Nanotubes, Carbon inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; naringin promotes the reaction [Glucose results in increased secretion of INS1 protein] naringin affects the expression of INS1 protein |
CTD |
PMID:24880026 PMID:29658312 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased phosphorylation of IRS1 protein] |
CTD |
PMID:22198281 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin promotes the reaction [JUN protein binds to BMP2 promoter]]; CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]]; JUN protein affects the reaction [naringin results in increased expression of BMP2 mRNA]; JUN protein affects the reaction [naringin results in increased expression of BMP2 protein]; naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]; naringin promotes the reaction [JUN protein binds to BMP2 promoter]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]] naringin results in increased expression of JUN mRNA |
CTD |
PMID:18495116 PMID:35166444 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Doxorubicin results in decreased expression of KEAP1 protein] |
CTD |
PMID:36811345 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of LCAT protein] |
CTD |
PMID:16906524 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased expression of LDHA protein] |
CTD |
PMID:17188415 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldhb |
lactate dehydrogenase B |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased expression of LDHB protein] |
CTD |
PMID:17188415 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lep |
leptin |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [Dietary Fats results in increased expression of LEP protein] [naringin co-treated with Hesperidin] results in decreased expression of LEP protein; naringin inhibits the reaction [Glucose results in increased expression of LEP protein] |
CTD |
PMID:21820093 PMID:22198281 PMID:24399619 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO EXP |
naringin affects the reaction [LEPR protein affects the abundance of Glucose]; naringin affects the reaction [LEPR protein affects the activity of FASN protein]; naringin affects the reaction [LEPR protein affects the activity of G6PD protein]; naringin affects the reaction [LEPR protein affects the activity of HMGCR protein]; naringin affects the reaction [LEPR protein affects the expression of G6PC1 mRNA]; naringin affects the reaction [LEPR protein affects the expression of GCK mRNA]; naringin affects the reaction [LEPR protein affects the expression of PCK1 mRNA]; naringin affects the reaction [LEPR protein affects the expression of PPARG protein]; naringin affects the reaction [LEPR protein affects the expression of SLC2A2 protein]; naringin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] naringin inhibits the reaction [Glucose results in increased expression of LEPR protein] |
CTD |
PMID:16427799 PMID:24399619 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of LHB protein] |
CTD |
PMID:36598108 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of LPL protein] |
CTD |
PMID:16906524 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
EXP |
[NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in increased expression of MAOA protein; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of MAOA protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of MAOA protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of MAOA protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of MAOA protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of MAOA protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of MAOA protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein] naringin results in decreased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein] naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18296682 PMID:18951945 PMID:21835177 PMID:22198281 PMID:22766066 PMID:22965302 PMID:25773745 PMID:26721195 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK10 protein] |
CTD |
PMID:22198281 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in increased expression of MAPK14 mRNA] |
CTD |
PMID:36598108 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in decreased phosphorylation of MAPK3 protein naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18296682 PMID:18951945 PMID:21835177 PMID:22198281 PMID:22766066 PMID:22965302 PMID:25773745 PMID:26721195 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:22198281 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:22198281 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mir126a |
microRNA 126a |
multiple interactions increases expression |
ISO |
MIR126 mRNA affects the reaction [naringin results in decreased expression of VCAM1 mRNA] naringin results in increased expression of MIR126 mRNA |
CTD |
PMID:24975661 |
|
NCBI chr 3:9,415,063...9,415,180
Ensembl chr 3:9,415,063...9,415,180
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
naringin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:26721195 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO EXP |
naringin inhibits the reaction [Paraquat results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [Paraquat results in increased expression of MMP9 protein] naringin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; naringin results in decreased expression of and results in decreased activity of MMP9 protein naringin inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; naringin inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MMP9 protein] |
CTD |
PMID:19810018 PMID:22985397 PMID:23603004 PMID:25866363 PMID:26721195 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
naringin inhibits the reaction [Tobacco Smoke Pollution results in increased activity of MPO protein] |
CTD |
PMID:22985397 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions |
ISO |
naringin inhibits the reaction [Cadmium Chloride results in increased expression of MT3 protein] |
CTD |
PMID:28422390 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
naringin inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein] |
CTD |
PMID:19810018 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
naringin inhibits the reaction [EGF protein results in increased expression of MUC5AC mRNA]; naringin inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] naringin inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased secretion of MUC5AC protein] |
CTD |
PMID:22766066 PMID:31301536 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [naringin affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [naringin affects the localization of NFE2L2 protein]; [naringin co-treated with 3-nitropropionic acid] affects the localization of NFE2L2 protein; naringin inhibits the reaction [Oxaliplatin results in decreased expression of NFE2L2 mRNA]; naringin inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2 mRNA]; naringin promotes the reaction [[Oxygen deficiency co-treated with Oxygen] affects the localization of NFE2L2 protein]; rottlerin inhibits the reaction [naringin affects the localization of NFE2L2 protein] CHAC2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]]; naringin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]; naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein]]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of BAX protein]]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in increased expression of JUN protein]]; NFE2L2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]]; NFE2L2 protein promotes the reaction [naringin promotes the reaction [Acetaminophen results in increased expression of NFE2L2 protein]]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:22871521 PMID:25773745 PMID:27174133 PMID:35166444 PMID:35179299 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
naringin inhibits the reaction [Cisplatin results in increased expression of NFKB1 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:26120027 PMID:26612654 PMID:38037725 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
affects degradation multiple interactions |
ISO |
naringin affects the degradation of NFKBIA protein naringin inhibits the reaction [TNFSF11 protein results in increased degradation of NFKBIA protein] |
CTD |
PMID:21835177 PMID:25117567 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
affects expression multiple interactions |
ISO EXP |
naringin affects the expression of NOS2 mRNA naringin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] naringin inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]; naringin inhibits the reaction [Cisplatin results in increased expression of NOS2 mRNA]; naringin inhibits the reaction [Oxaliplatin results in increased expression of NOS2 mRNA] |
CTD |
PMID:16137700 PMID:22871521 PMID:25117567 PMID:26612654 PMID:38037725 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
naringin inhibits the reaction [TNF protein results in increased expression of NOX4 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 protein] |
CTD |
PMID:25391245 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
EXP |
[naringin co-treated with 3-nitropropionic acid] results in increased expression of NQO1 mRNA naringin results in increased expression of NQO1 mRNA |
CTD |
PMID:22871521 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in decreased activity of OGDH protein] |
CTD |
PMID:17994577 |
|
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of PCK1 mRNA] |
CTD |
PMID:16427799 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pde5a |
phosphodiesterase 5A |
multiple interactions |
EXP |
naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased activity of PDE5A protein]; naringin inhibits the reaction [[potassium bromate co-treated with Caffeine] results in increased activity of PDE5A protein]; naringin inhibits the reaction [bisphenol A promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of PDE5A protein]]; naringin inhibits the reaction [bisphenol A results in increased activity of PDE5A protein]; naringin inhibits the reaction [Caffeine results in increased activity of PDE5A protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [bisphenol A results in increased activity of PDE5A protein]]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased activity of PDE5A protein]; naringin inhibits the reaction [potassium bromate results in increased activity of PDE5A protein] |
CTD |
PMID:32172062 PMID:32428650 PMID:32810514 PMID:37865952 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in increased expression of PIK3CA mRNA] |
CTD |
PMID:30878453 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in increased expression of PIK3R1 mRNA] |
CTD |
PMID:30878453 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO EXP |
naringin affects the reaction [LEPR protein affects the expression of PPARG protein]; naringin inhibits the reaction [Dietary Fats results in increased expression of PPARG mRNA] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA]; naringin inhibits the reaction [Quinolinic Acid results in decreased expression of PPARG mRNA] |
CTD |
PMID:16427799 PMID:22198281 PMID:30130594 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
naringin inhibits the reaction [Ethanol results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:18793633 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkcd |
protein kinase C, delta |
increases phosphorylation multiple interactions |
EXP |
naringin results in increased phosphorylation of PRKCD protein rottlerin inhibits the reaction [naringin results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:25773745 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression multiple interactions |
ISO EXP |
naringin affects the expression of PTGS2 mRNA; naringin affects the expression of PTGS2 protein naringin inhibits the reaction [Acetaminophen results in increased expression of PTGS2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of PTGS2 protein]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] naringin inhibits the reaction [3-nitropropionic acid results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16137700 PMID:22871521 PMID:25117567 PMID:35166444 PMID:35179299 PMID:36811345 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions increases activity increases phosphorylation |
ISO EXP |
RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] RAF1 protein affects the reaction [naringin results in decreased expression of CDK2 protein]; RAF1 protein affects the reaction [naringin results in decreased expression of CDK4 protein]; RAF1 protein affects the reaction [naringin results in increased expression of CDKN1A protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [naringin results in increased phosphorylation of MAPK3 protein] naringin results in increased activity of RAF1 protein naringin results in increased phosphorylation of RAF1 protein |
CTD |
PMID:18296682 PMID:18951945 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [EGF protein affects the localization of RELA protein] naringin affects the expression of and affects the activity of RELA protein; naringin inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein] |
CTD |
PMID:21500970 PMID:22766066 PMID:22965302 PMID:25117567 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
naringin inhibits the reaction [AICA ribonucleotide results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [Okadaic Acid results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:15342961 PMID:19810018 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
ISO EXP |
naringin results in increased expression of RUNX2 mRNA naringin inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein] DKK1 protein inhibits the reaction [naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA]]; naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of RUNX2 mRNA] fulvestrant inhibits the reaction [naringin results in increased expression of RUNX2 mRNA] |
CTD |
PMID:21741227 PMID:23596885 PMID:24915843 PMID:26482937 PMID:30878453 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
naringin inhibits the reaction [Ethanol results in increased expression of SIRT1 mRNA] naringin inhibits the reaction [Doxorubicin results in decreased expression of SIRT1 protein]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]] |
CTD |
PMID:18793633 PMID:36811345 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of SLC2A2 protein] |
CTD |
PMID:16427799 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
naringin affects the reaction [LEPR protein affects the expression of SLC2A4 protein] |
CTD |
PMID:16427799 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
naringin inhibits the reaction [SLCO1A2 protein alternative form results in increased uptake of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased transport of estrone sulfate]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Quercetin]; naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Quinine] |
CTD |
PMID:24947867 PMID:25466967 PMID:27504015 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
naringin inhibits the reaction [SLCO1B3 protein results in increased import of Sulfobromophthalein]; naringin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea] |
CTD |
PMID:21256917 PMID:22394605 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP |
naringin inhibits the reaction [sodium arsenite results in increased expression of SMAD3 mRNA] |
CTD |
PMID:27174133 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
CHAC2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]]; naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; naringin inhibits the reaction [Ferric Compounds results in decreased activity of SOD2 protein]; NFE2L2 protein promotes the reaction [naringin inhibits the reaction [Acetaminophen results in decreased expression of SOD2 protein]] |
CTD |
PMID:21345335 PMID:35166444 PMID:35179299 PMID:36811345 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression multiple interactions |
EXP ISO |
naringin results in increased expression of SP7 mRNA naringin inhibits the reaction [Hydrogen Peroxide results in decreased expression of SP7 mRNA] fulvestrant inhibits the reaction [naringin results in increased expression of SP7 mRNA] |
CTD |
PMID:23596885 PMID:26482937 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spn |
sialophorin |
multiple interactions increases expression decreases expression |
EXP |
[bisphenol A co-treated with naringin] results in decreased expression of SPN protein; [NG-Nitroarginine Methyl Ester co-treated with bisphenol A co-treated with naringin] results in decreased expression of SPN protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in decreased expression of SPN protein; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of SPN protein]; naringin inhibits the reaction [bisphenol A results in increased expression of SPN protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of SPN protein] naringin results in increased expression of SPN protein naringin results in decreased expression of SPN protein |
CTD |
PMID:32172062 PMID:32428650 |
|
NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression increases secretion multiple interactions |
ISO EXP |
naringin results in increased expression of SPP1 mRNA; naringin results in increased expression of SPP1 protein naringin results in increased secretion of SPP1 protein fulvestrant inhibits the reaction [naringin results in increased secretion of SPP1 protein] |
CTD |
PMID:18495116 PMID:23596885 PMID:24915843 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
naringin inhibits the reaction [Acrylamide results in decreased expression of STAR mRNA] |
CTD |
PMID:36598108 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
affects expression |
ISO |
naringin affects the expression of STAT3 mRNA; naringin affects the expression of STAT3 protein |
CTD |
PMID:25117567 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions affects expression |
ISO EXP |
naringin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] naringin inhibits the reaction [Cyclophosphamide results in increased expression of TGFB1 mRNA]; naringin inhibits the reaction [sodium arsenite results in increased expression of TGFB1 mRNA] naringin affects the expression of TGFB1 mRNA |
CTD |
PMID:23603004 PMID:25117567 PMID:27174133 PMID:33992719 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
naringin inhibits the reaction [Paraquat results in increased expression of TIMP1 mRNA]; naringin inhibits the reaction [Paraquat results in increased expression of TIMP1 protein] |
CTD |
PMID:23603004 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression |
ISO EXP |
naringin inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA]; naringin inhibits the reaction [Dietary Fats results in increased expression of TNF protein]; naringin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; naringin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; naringin inhibits the reaction [Paraquat results in increased expression of TNF mRNA] [naringin co-treated with Pioglitazone] inhibits the reaction [Quinolinic Acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TNF protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of TNF protein]; naringin inhibits the reaction [Acrylamide results in increased expression of TNF protein]; naringin inhibits the reaction [bisphenol A results in increased expression of TNF protein]; naringin inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; naringin inhibits the reaction [Cisplatin results in increased expression of TNF protein]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of TNF protein]; naringin inhibits the reaction [Oxaliplatin results in increased expression of TNF mRNA]; naringin inhibits the reaction [Quinolinic Acid results in increased expression of TNF mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; naringin inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of AKT1 protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; naringin inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; naringin inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; naringin inhibits the reaction [TNF protein results in increased secretion of IL6 protein]; naringin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TNF protein] naringin affects the expression of TNF protein naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] affects the localization of RELA protein]; naringin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CCL5 protein]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of CYBA protein]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of NOX4 protein]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] naringin affects the expression of TNF mRNA |
CTD |
PMID:16137700 PMID:19810018 PMID:21500970 PMID:22198281 PMID:22871521 PMID:22985397 PMID:23603004 PMID:24131540 PMID:24880026 PMID:25117567 PMID:25391245 PMID:26120027 PMID:26612654 PMID:30130594 PMID:32172062 PMID:32428650 PMID:32810514 PMID:35166444 PMID:35179299 PMID:36598108 PMID:36811345 PMID:38037725 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
decreases expression |
ISO |
naringin results in decreased expression of TNFRSF11A mRNA |
CTD |
PMID:24376342 |
|
NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
naringin inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; naringin inhibits the reaction [Dexamethasone results in increased expression of TNFRSF11B protein] |
CTD |
PMID:30878453 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ACP5 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of ATP6V0D2 mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CALCR mRNA]; naringin inhibits the reaction [[TNFSF11 protein co-treated with CSF1R protein] results in increased expression of CTSK mRNA]; naringin inhibits the reaction [TNFSF11 protein results in increased degradation of NFKBIA protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; naringin inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21835177 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
naringin inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] |
CTD |
PMID:17188415 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions decreases expression |
ISO EXP |
naringin results in increased expression of TP53 mRNA naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]; SIRT1 protein affects the reaction [naringin inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]] naringin results in decreased expression of TP53 protein [bisphenol A co-treated with naringin] results in decreased expression of TP53 protein; [NG-Nitroarginine Methyl Ester co-treated with naringin] results in decreased expression of TP53 protein; naringin inhibits the reaction [[bisphenol A co-treated with NG-Nitroarginine Methyl Ester] results in increased expression of TP53 protein]; naringin inhibits the reaction [[NG-Nitroarginine Methyl Ester co-treated with bisphenol A] results in increased expression of TP53 protein]; naringin inhibits the reaction [Acrylamide results in increased expression of TP53 mRNA]; naringin inhibits the reaction [bisphenol A results in increased expression of TP53 protein]; naringin inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA]; naringin inhibits the reaction [NG-Nitroarginine Methyl Ester results in increased expression of TP53 protein] |
CTD |
PMID:22847135 PMID:26120027 PMID:26612654 PMID:32172062 PMID:32428650 PMID:32810514 PMID:36598108 PMID:36811345 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TSLP mRNA]; naringin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TSLP protein] |
CTD |
PMID:24131540 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
naringin inhibits the reaction [Dietary Fats results in increased expression of UCP2 mRNA] |
CTD |
PMID:22198281 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
MIR126 mRNA affects the reaction [naringin results in decreased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; naringin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] naringin results in decreased expression of VCAM1 mRNA; naringin results in decreased expression of VCAM1 protein |
CTD |
PMID:24975661 PMID:25391245 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfc |
vascular endothelial growth factor C |
affects expression |
EXP |
naringin affects the expression of VEGFC mRNA |
CTD |
PMID:24880026 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases activity increases expression |
ISO |
[8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein; fulvestrant inhibits the reaction [[8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein] 8-prenylnaringenin results in increased activity of ALPL protein 8-prenylnaringenin results in increased expression of ALPL mRNA |
CTD |
PMID:12650720 PMID:16019205 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
C3 |
complement C3 |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of C3 mRNA |
CTD |
PMID:16522720 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions |
ISO |
8-prenylnaringenin inhibits the reaction [CBR1 protein results in increased metabolism of Daunorubicin]; 8-prenylnaringenin inhibits the reaction [CBR1 protein results in increased reduction of 2,3-hexanedione] |
CTD |
PMID:30849340 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of CGA mRNA |
CTD |
PMID:16522720 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Csn2 |
casein beta |
increases expression multiple interactions |
EXP |
8-prenylnaringenin results in increased expression of CSN2 mRNA Methylcholanthrene inhibits the reaction [8-prenylnaringenin results in increased expression of CSN2 mRNA] |
CTD |
PMID:26372666 |
|
NCBI chr14:20,322,581...20,329,818
Ensembl chr14:20,322,581...20,329,817
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity decreases expression |
ISO |
8-prenylnaringenin results in decreased activity of CYP1A1 protein 8-prenylnaringenin results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:19770484 PMID:32986415 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity increases expression |
ISO |
8-prenylnaringenin results in decreased activity of CYP1A2 protein 8-prenylnaringenin results in increased expression of CYP1A2 mRNA |
CTD |
PMID:15672752 PMID:19770484 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
8-prenylnaringenin results in decreased activity of CYP3A4 protein |
CTD |
PMID:19770484 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity decreases expression increases expression |
ISO EXP |
8-prenylnaringenin analog binds to and results in increased activity of ESR1 protein; 8-prenylnaringenin binds to and results in increased activity of ESR1 protein; [8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [8-prenylnaringenin results in decreased expression of ESR1 protein]; Fulvestrant inhibits the reaction [[8-prenylnaringenin binds to ESR1 protein] which results in increased activity of ALPL protein] 8-prenylnaringenin results in increased activity of ESR1 protein [Fulvestrant co-treated with 8-prenylnaringenin] results in increased expression of ESR1 mRNA; Fulvestrant inhibits the reaction [8-prenylnaringenin results in decreased expression of ESR1 protein] 8-prenylnaringenin results in increased expression of ESR1 mRNA |
CTD |
PMID:12623674 PMID:12650720 PMID:15876408 PMID:16076101 PMID:17149865 PMID:17716812 PMID:32986415 PMID:34848279 More...
|
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression increases activity multiple interactions increases expression |
EXP ISO |
8-prenylnaringenin results in decreased expression of ESR2 mRNA 8-prenylnaringenin results in increased activity of ESR2 protein 8-prenylnaringenin analog binds to and results in decreased activity of ESR2 protein; 8-prenylnaringenin binds to and results in increased activity of ESR2 protein 8-prenylnaringenin results in increased expression of ESR2 mRNA [Fulvestrant co-treated with 8-prenylnaringenin] results in increased expression of ESR2 mRNA |
CTD |
PMID:16076101 PMID:16522720 PMID:17149865 PMID:17716812 PMID:34848279 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of FSHB protein |
CTD |
PMID:16522720 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gnrhr |
gonadotropin releasing hormone receptor |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of GNRHR mRNA |
CTD |
PMID:16522720 |
|
NCBI chr14:21,856,871...21,874,861
Ensembl chr14:21,856,871...21,874,861
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
[Fulvestrant co-treated with 8-prenylnaringenin] results in decreased expression of IGF1 mRNA |
CTD |
PMID:34848279 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of IGF1R mRNA |
CTD |
PMID:16522720 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
8-prenylnaringenin results in decreased expression of IL6 mRNA |
CTD |
PMID:16019205 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kif11 |
kinesin family member 11 |
multiple interactions increases expression |
EXP |
Methylcholanthrene inhibits the reaction [8-prenylnaringenin results in increased expression of KIF11 mRNA] |
CTD |
PMID:26372666 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif18a |
kinesin family member 18A |
increases expression multiple interactions |
EXP |
8-prenylnaringenin results in increased expression of KIF18A mRNA Methylcholanthrene inhibits the reaction [8-prenylnaringenin results in increased expression of KIF18A mRNA] |
CTD |
PMID:26372666 |
|
NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582
|
|
G |
Kif2c |
kinesin family member 2C |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of KIF2C mRNA |
CTD |
PMID:26372666 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of LHB mRNA; 8-prenylnaringenin results in decreased expression of LHB protein |
CTD |
PMID:16522720 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
8-prenylnaringenin results in decreased expression of MKI67 mRNA |
CTD |
PMID:26372666 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
ISO EXP |
8-prenylnaringenin results in increased expression of PGR mRNA 8-prenylnaringenin results in increased expression of PGR mRNA; 8-prenylnaringenin results in increased expression of PGR protein Fulvestrant inhibits the reaction [8-prenylnaringenin results in increased expression of PGR mRNA] |
CTD |
PMID:16076101 PMID:16522720 PMID:16837889 PMID:34848279 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Prl |
prolactin |
increases expression |
EXP |
8-prenylnaringenin results in increased expression of PRL protein |
CTD |
PMID:16522720 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
8-prenylnaringenin results in increased expression of TFF1 mRNA |
CTD |
PMID:16019205 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
ISO |
8-prenylnaringenin results in increased expression of VWF mRNA |
CTD |
PMID:16019205 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|